In October, Mainz reported fiscal first-half loss per share had narrowed to $0.48 from $1 a year earlier, with revenue rising to $520,773 from $499,049. The company’s cash and cash equivalents ...

Mainz Biomed N.V. announced the pricing of a follow-on offering of 2,000,000 units, each consisting of one ordinary share (or pre-funded warrant), one Series A warrant, and one Series B warrant ...

Mainz BioMed NV. Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert ® in Europe. Operating loss decreased by 30% and net loss by 18%, driven by targeted ...

Mainz Biomed N.V. has announced the next phase in its PancAlert project, which aims to develop a non-invasive blood test for early pancreatic cancer detection. Following a successful discovery ...

Mainz Biomed's collaboration with Thermo Fisher aims to advance mRNA-based colorectal cancer screening technologies. ColoAlert improvements reduce retesting rates, delivering results in 2–3 days ...

Mainz Biomed (NASDAQ:MYNZ) has priced a follow-on offering of 2M units to raise gross proceeds of approximately $4M.Each unit, consisting of one ordinary share (or pre-funded warrant in lieu ...

Mainz Biomed MYNZ, a company that specializes in developing molecular genetic diagnostic solutions for life-threatening conditions, has created ColoAlert®, ...

BERKELEY, Calif. and MAINZ, Germany, March 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic ...

View Mainz Biomed N.V. MYNZ stock quote prices, financial information, real-time forecasts, and company news from CNN.

Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous LesionsPoster presentation showing new data on 690 subjects ...

View Mainz Biomed N.V. MYNZ stock quote prices, financial information, real-time forecasts, and company news from CNN.